Safety and Efficacy of PegIntron and Rebetol Combination Therapy in Patients With Chronic Hepatitis C in Japan (Study P04505)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00724295|
Recruitment Status : Completed
First Posted : July 29, 2008
Last Update Posted : February 4, 2015
This is a post-marketing surveillance of patients with chronic hepatitis C treated with PegIntron and Rebetol combination therapy in clinical practice in Japan. The objective of the study is to evaluate the safety and efficacy of the combination therapy. The study will also compare the safety profile of the combination therapy among elderly patients and younger patients.
Post-marketing surveys are not considered applicable clinical trials and thus the results of this survey will not be posted at its conclusion. The results will be submitted to public health officials as required by applicable national and international laws.
|Condition or disease||Intervention/treatment|
|Hepatitis C, Chronic Hepatitis C||Drug: peginterferon alfa-2b Drug: ribavirin|
|Study Type :||Observational|
|Actual Enrollment :||1077 participants|
|Official Title:||PEG Intron/REBETOL Combination Therapy Special Investigation -Investigation on the Safety and Efficacy of PegIntron and REBETOL Combination Therapy in Patients With Chronic Hepatitis C-|
|Study Start Date :||April 2005|
|Actual Primary Completion Date :||December 2008|
|Actual Study Completion Date :||December 2008|
Overall study population
Drug: peginterferon alfa-2b
PegIntron powder (reconstituted) administered in accordance with approved labeling; Subcutaneous injection of 1.5 ug/kg once weekly for 48 weeks.
Other Names:Drug: ribavirin
Rebetol capsule administered orally twice daily in accordance with approved labeling (weight based dosing). Dosing duration 48 weeks.
- Overall incidence of adverse events and adverse drug reactions. [ Time Frame: From the time the informed consent is signed and up to 30 days after study completion or discontinuation. Treatment period is 48 weeks with a 24 week post dose followup. ]
- Assessment of trends of adverse drug reactions by patient factors and concomitant medications. Incidence of adverse events (AEs) in the elderly vs younger patients; rates of hematologic AEs; dose reduction and discontinuation rates. [ Time Frame: From the time the informed consent is signed and up to 30 days after study completion or discontinuation. Treatment period is 48 weeks with a 24 week post dose followup. ]
- Sustained virologic response rate and improvement of ALT (alanine transaminase). [ Time Frame: Assessed at the end-of-treatment and at 24 weeks post-treatment. ]